Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease.

Clin Exp NephrolJun 8, 2026 (epub)
Clinical ResearchNephrologyOpen access

Chie Saito, Kaori Mase, Shun Ishibashi et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of cilostazol on renal function and long-term outcomes in 12 patients with advanced chronic kidney disease (CKD) due to nephrosclerosis. After one year, the mean annual decline in glomerular filtration rate (GFR) was significantly slower in the cilostazol group (-2.72 mL/min/1.73 m²/year) compared to the aspirin-only group (-3.84 mL/min/1.73 m²/year).

Key findings

  • GFR declined significantly in the aspirin group but not in the cilostazol group after one year.
  • The annual rate of GFR decline was significantly slower in the cilostazol group compared to the aspirin group.
  • Over 6.7 years, renal replacement therapy was initiated in 2 patients in the cilostazol group versus 4 in the aspirin group.
  • No cardiovascular events occurred in the cilostazol group, while two cerebral infarctions occurred in the aspirin group.

Why it matters

Understanding the potential renoprotective effects of cilostazol in patients with advanced CKD could inform treatment strategies aimed at slowing renal function decline and reducing cardiovascular risks.

Source

PubMed · PMID 42258055Free full text on PubMed Central

Published in Clin Exp Nephrol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.